102 related articles for article (PubMed ID: 35419733)
1. Combined analysis of clinical and laboratory markers to predict the risk of venous thromboembolism in patients with IDH1 wild-type glioblastoma.
Huang Y; Ding H; Luo M; Li S; Xie C; Zhong Y; Li Z
Support Care Cancer; 2022 Jul; 30(7):6063-6069. PubMed ID: 35419733
[TBL] [Abstract][Full Text] [Related]
2. Combination of isocitrate dehydrogenase 1 (IDH1) mutation and podoplanin expression in brain tumors identifies patients at high or low risk of venous thromboembolism.
Mir Seyed Nazari P; Riedl J; Preusser M; Posch F; Thaler J; Marosi C; Birner P; Ricken G; Hainfellner JA; Pabinger I; Ay C
J Thromb Haemost; 2018 Jun; 16(6):1121-1127. PubMed ID: 29676036
[TBL] [Abstract][Full Text] [Related]
3. The Role of EGFR Amplification in Deep Venous Thrombosis Occurrence in IDH Wild-Type Glioblastoma.
Kaye B; Ali A; Correa Bastianon Santiago RA; Ibrahim B; Isidor J; Awad H; Sabahi M; Obrzut M; Adada B; Ranjan S; Borghei-Razavi H
Curr Oncol; 2023 May; 30(5):4946-4956. PubMed ID: 37232831
[No Abstract] [Full Text] [Related]
4. Risk of Venous Thromboembolism in Grade II-IV Gliomas as a Function of Molecular Subtype.
Diaz M; Jo J; Smolkin M; Ratcliffe SJ; Schiff D
Neurology; 2021 Feb; 96(7):e1063-e1069. PubMed ID: 33361259
[TBL] [Abstract][Full Text] [Related]
5. Combined analysis of TERT, EGFR, and IDH status defines distinct prognostic glioblastoma classes.
Labussière M; Boisselier B; Mokhtari K; Di Stefano AL; Rahimian A; Rossetto M; Ciccarino P; Saulnier O; Paterra R; Marie Y; Finocchiaro G; Sanson M
Neurology; 2014 Sep; 83(13):1200-6. PubMed ID: 25150284
[TBL] [Abstract][Full Text] [Related]
6. Podoplanin Expression and IDH-Wildtype Status Predict Venous Thromboembolism in Patients with High-Grade Gliomas in the Early Postoperative Period.
Watanabe J; Natsumeda M; Okada M; Kanemaru Y; Tsukamoto Y; Oishi M; Kakita A; Fujii Y
World Neurosurg; 2019 Aug; 128():e982-e988. PubMed ID: 31100523
[TBL] [Abstract][Full Text] [Related]
7. Determining venous thromboembolism risk in patients with adult-type diffuse glioma.
Burdett KB; Unruh D; Drumm M; Steffens A; Lamano J; Judkins J; Schwartz M; Javier R; Amidei C; Lipp ES; Peters KB; Lai A; Eldred BSC; Heimberger AB; McCortney K; Scholtens DM; Horbinski C
Blood; 2023 Mar; 141(11):1322-1336. PubMed ID: 36399711
[TBL] [Abstract][Full Text] [Related]
8. Low MGMT digital expression is associated with a better outcome of IDH1 wildtype glioblastomas treated with temozolomide.
Gomes I; Moreno DA; Dos Reis MB; da Silva LS; Leal LF; Gonçalves GM; Pereira CA; Oliveira MA; de Medeiros Matsushita M; Reis RM
J Neurooncol; 2021 Jan; 151(2):135-144. PubMed ID: 33400009
[TBL] [Abstract][Full Text] [Related]
9. Association between IDH mutational status and tumor-associated epilepsy or venous thromboembolism in patients with grade II and III astrocytoma.
Osada Y; Saito R; Miyata S; Shoji T; Shibahara I; Kanamori M; Sonoda Y; Kumabe T; Watanabe M; Tominaga T
Brain Tumor Pathol; 2021 Jul; 38(3):218-227. PubMed ID: 34269949
[TBL] [Abstract][Full Text] [Related]
10. Cerebellar glioblastoma: a clinical series with contemporary molecular analysis.
Hong B; Banan R; Christians A; Nakamura M; Lalk M; Lehmann U; Hartmann C; Krauss JK
Acta Neurochir (Wien); 2018 Nov; 160(11):2237-2248. PubMed ID: 30203362
[TBL] [Abstract][Full Text] [Related]
11. IDH mutation status and the development of venous thromboembolism in astrocytoma patients.
Mandel JJ; Youssef M; Yust-Katz S; Patel AJ; Jalali A; Li Z; Wu J; Ludmir EB; de Groot JF
J Neurol Sci; 2021 Aug; 427():117538. PubMed ID: 34146775
[TBL] [Abstract][Full Text] [Related]
12. Sex-specific clinicopathological significance of novel (Frizzled-7) and established (MGMT, IDH1) biomarkers in glioblastoma.
Schiffgens S; Wilkens L; Brandes AA; Meier T; Franceschi E; Ermani M; Hartmann C; Sandalcioglu IE; Dumitru CA
Oncotarget; 2016 Aug; 7(34):55169-55180. PubMed ID: 27409829
[TBL] [Abstract][Full Text] [Related]
13. Venous Thromboembolism in Brain Tumors: Risk Factors, Molecular Mechanisms, and Clinical Challenges.
Riedl J; Ay C
Semin Thromb Hemost; 2019 Jun; 45(4):334-341. PubMed ID: 31041803
[TBL] [Abstract][Full Text] [Related]
14. Glioblastoma with oligodendroglioma component (GBM-O): molecular genetic and clinical characteristics.
Appin CL; Gao J; Chisolm C; Torian M; Alexis D; Vincentelli C; Schniederjan MJ; Hadjipanayis C; Olson JJ; Hunter S; Hao C; Brat DJ
Brain Pathol; 2013 Jul; 23(4):454-61. PubMed ID: 23289977
[TBL] [Abstract][Full Text] [Related]
15. IDH mutation and MGMT promoter methylation are associated with the pseudoprogression and improved prognosis of glioblastoma multiforme patients who have undergone concurrent and adjuvant temozolomide-based chemoradiotherapy.
Li H; Li J; Cheng G; Zhang J; Li X
Clin Neurol Neurosurg; 2016 Dec; 151():31-36. PubMed ID: 27764705
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of MGMT promoter methylation and TP53 mutation in glioblastomas depends on IDH1 mutation.
Wang K; Wang YY; Ma J; Wang JF; Li SW; Jiang T; Dai JP
Asian Pac J Cancer Prev; 2014; 15(24):10893-8. PubMed ID: 25605197
[TBL] [Abstract][Full Text] [Related]
17. Relationship between tumor enhancement, edema, IDH1 mutational status, MGMT promoter methylation, and survival in glioblastoma.
Carrillo JA; Lai A; Nghiemphu PL; Kim HJ; Phillips HS; Kharbanda S; Moftakhar P; Lalaezari S; Yong W; Ellingson BM; Cloughesy TF; Pope WB
AJNR Am J Neuroradiol; 2012 Aug; 33(7):1349-55. PubMed ID: 22322613
[TBL] [Abstract][Full Text] [Related]
18. Targeted DNA sequencing to identify genetic aberrations in glioblastoma that underlie venous thromboembolism; a cohort study.
Kapteijn MY; Kaptein FHJ; Stals MAM; Klaase EE; García-Ortiz I; van Eijk R; Ruano D; van Duinen SG; Cannegieter SC; Taphoorn MJB; Dirven L; Koekkoek JAF; Klok FA; Versteeg HH; Buijs JT
Thromb Res; 2023 Jan; 221():10-18. PubMed ID: 36435047
[TBL] [Abstract][Full Text] [Related]
19. Isocitrate Dehydrogenase Mutations are Better Prognostic Marker than O6-methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastomas - a Retrospective, Single-centre Molecular Genetics Study of Gliomas.
Houdova Megova M; Drábek J; Dwight Z; Trojanec R; Koudeláková V; Vrbková J; Kalita O; Mlcochova S; Rabcanova M; Hajdúch M
Klin Onkol; 2017; 30(5):361-371. PubMed ID: 29031038
[TBL] [Abstract][Full Text] [Related]
20. Human TERT promoter mutation enables survival advantage from MGMT promoter methylation in IDH1 wild-type primary glioblastoma treated by standard chemoradiotherapy.
Nguyen HN; Lie A; Li T; Chowdhury R; Liu F; Ozer B; Wei B; Green RM; Ellingson BM; Wang HJ; Elashoff R; Liau LM; Yong WH; Nghiemphu PL; Cloughesy T; Lai A
Neuro Oncol; 2017 Mar; 19(3):394-404. PubMed ID: 27571882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
